Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 sept. 2011 13h15 HE | Source: Mateon Therapeutics

OXiGENE Presents Data Confirming Survival Benefit of ZYBRESTAT in Patients With Anaplastic Thyroid Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
09 sept. 2011 16h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Changes to Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
07 sept. 2011 16h30 HE | Source: Mateon Therapeutics

OXiGENE to Present Additional ZYBRESTAT(TM) Survival Data at European Thyroid Association Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 7, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
01 sept. 2011 08h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Restructuring to Focus Resources on Promising Earlier Stage Clinical Programs

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
10 août 2011 16h00 HE | Source: Mateon Therapeutics

OXiGENE Reports Second Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
03 août 2011 17h11 HE | Source: Mateon Therapeutics

OXiGENE Reports Second Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
06 juin 2011 16h45 HE | Source: Mateon Therapeutics

ZYBRESTAT(TM) Results Suggest Improvement in Overall Survival in Phase 2/3 Study in Anaplastic Thyroid Cancer

Median Overall Survival Extended by 1.2 Months for ZYBRESTAT Patients One-Year Survival Almost Tripled With ZYBRESTAT Plus Chemotherapy Compared to Chemotherapy Alone (26% vs....
06 juin 2011 08h00 HE | Source: Mateon Therapeutics

OXiGENE Complies With NASDAQ Listing Requirements

SOUTH SAN FRANCISCO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
04 juin 2011 15h00 HE | Source: Mateon Therapeutics

OXiGENE Reports Encouraging Data From Phase 2 Trial of ZYBRESTAT(TM) in Non-small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., June 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
18 mai 2011 08h00 HE | Source: Mateon Therapeutics

OXiGENE Announces Clinical Data From FACT and FALCON Studies to be Presented at ASCO

SOUTH SAN FRANCISCO, Calif., May 18, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...

Page précédente